---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-178806"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:53:00.286906+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q1 net loss $18.9M, CFO retiring, CAMP4 license terminated, pociredir trial planned H2 2026

## Summary
- CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.
- Terminated CAMP4 license for Diamond-Blackfan anemia program; no further milestone/royalty payments.
- Q1 net loss $18.9M ($17.7M Q1 2025); cash $333.3M, runway into 2029.
- Positive pociredir Phase 1b data: HbF induction, hemolysis/anemia improvements; registration-enabling trial H2 2026.
- Board appointed Josh Lehrer M.D., independent, receives option for 64,000 shares at $8.08.

## SEC filing metadata
- accession: 0001193125-26-178806
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/0001193125-26-178806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/fulc-20260423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-178806
- JSON: https://secwatch.observer/filing/0001193125-26-178806.json
- Plain text: https://secwatch.observer/filing/0001193125-26-178806.txt

## Source-grounded claims
- claim_id: aa48098a738dd0a50f37e4fa3ed9c99888cb8b5b
  claim: Fulcrum Therapeutics, Inc. reported first quarter of 2026 results: net income $18.9 million.
  evidence_excerpt: higher employee compensation costs, including $0.3 million of increased stock-based compensation expense, as well as higher professional services costs. • Net Loss: Net loss was $18.9 million for the three months ended March 31, 2026, compared to a net loss of $17.7 million for the three months ended March 31, 2025. Cash Runway Guidance Based on its current operating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/0001193125-26-178806-index.htm
- claim_id: 7438de5fd1b870b56fc4b094280e6bc8273e66ea
  claim: Fulcrum Therapeutics, Inc. terminated CAMP4 License with CAMP4 Therapeutics Corp. (effective 2026-04-23).
  evidence_excerpt: On April 23, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, provided written notice to CAMP4 Therapeutics Corp., or CAMP4, of termination of the License Agreement dated July 5, 2023, between Fulcrum and CAMP4, or the CAMP4 License, which termination will be effective in accordance with the terms of such agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/0001193125-26-178806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.